You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of July 31, 2018

  • Discovery Projects
  • Phase 1
    15
  • Phase 2
    6
  • Phase 3
    17
  • Registration
    5
  • Total43
 
Compound Name
Indicationsort descending
Phase
Submission Type
Compound Type
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 3 Product Enhancement Biologic
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Metastatic Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Bispecific protein
Go to clinical trial
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic Castration-Resistant Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Platinum Resistant/Refractory Ovarian Cancer (Biologic) Phase 3 Product Enhancement Biologic
  •  
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options